TYPE OF FUNDING: Growth Equity
LOCATION OF THE COMPANY: United States (North America)
VOLUME: USD 53 Million
DESCRIPTION OF THE COMPANY:
The client is a Healthcare Technology company developing next-generation treatment equipment. The company is developing a next-generation cancer treatment equipment manufacturer that’s first of its kind providing both Proton Imaging as well as treatment capabilities. This compact, lightweight, synchrotron technology is ready to take off.
* The company has approximately 100 patents.
* The company will use funds for vendor acquisition, production facility, research, and global S&M channels.
WHAT IS IT FOR THE INVESTORS:
* It expects a significant ROI over the next 5 years and an IRR of approximately 56%.
* Exit target by IPO listing or acquisition by 2025 by global players. The MOIC is expected to be 9.15 times.